Patents by Inventor Kirk Raymond Dinehart

Kirk Raymond Dinehart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms and compositions of CFTR modulators
    Patent number: 11155533
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: October 26, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
    Publication number: 20200392109
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: March 25, 2020
    Publication date: December 17, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • Crystalline forms and compositions of CFTR modulators
    Patent number: 10654829
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 19, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
    Publication number: 20190119253
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereofare disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 25, 2019
    Applicant: Vertex Pharamceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang
  • Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
    Patent number: 9045425
    Abstract: The present invention relates to crystalline solvate forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: June 2, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Luisi, Sneha Ghanshyam Arekar, Adriana Costache, Kirk Raymond Dinehart, Steven C. Johnston, Bobbianna J. Neubert-Langille
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20150065439
    Abstract: Described herein are compositions that can include Compound 1 or Form J of Compound 1, or a pharmaceutically acceptable salt of the aforementioned compounds. Also, described herein is a method of treating a HCV infection in a subject that can include administering to the subject a composition that includes Compound 1 or Form J of Compound 1, or a pharmaceutically acceptable salt of the aforementioned compounds.
    Type: Application
    Filed: February 27, 2014
    Publication date: March 5, 2015
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tapan Sanghvi, Kirk Raymond Dinehart
  • SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE
    Publication number: 20140142312
    Abstract: The present invention relates to crystalline solvate forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 22, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Luisi, Sneha Arekar, Adriana Costache, Kirk Raymond Dinehart, Steven C. Johnston, Bobbianna J. Neubert-Langille
  • Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
    Patent number: 8674108
    Abstract: The present invention relates to crystalline solvate forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: March 18, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Luisi, Sneha Ghanshyam Arekar, Adriana Costache, Kirk Raymond Dinehart, Steven C. Johnston, Bobbianna J. Neubert-Langille
  • Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
    Publication number: 20130281487
    Abstract: The present invention relates to crystalline solvate forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 24, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Luisi, Sneha Ghanshyam Arekar, Adriana Costache, Kirk Raymond Dinehart, Steven C. Johnston, Bobbianna J. Neubert-Lagille